Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT05288062 | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Sep 28, 2026 |
| clinicaltrials |
| NCT04601584 | GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL | terminated | Phase 1 / Phase 2 | 14 | AO GENERIUMINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | terminated | Phase 1 / Phase 2 | 57 | Jennifer AmengualOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06704152 | BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | terminated | Phase 1 / Phase 2 | 2 | BlueSphere Bio, IncINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | terminated | Phase 1 / Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03488225 | Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02967276 | Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma(METDEXA-MM) | terminated | Phase 2 | 28 | University of Campinas, BrazilOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma(EPCORE DLBCL-3) | terminated | Phase 2 | 111 | GenmabINDUSTRY | 12 | Jul 2, 2026 | clinicaltrials |
| NCT04788043 | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | terminated | Phase 2 | 8 | Ranjana AdvaniOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma(RELATIVITY-069) | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06381830 | Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 8 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04758650 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis(MITRAS) | terminated | Phase 2 | 29 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT01135329 | Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | terminated | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03757221 | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma(IDARA) | terminated | Phase 2 | 55 | University Hospital, CaenOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03808610 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03547700 | Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) | terminated | Phase 1 / Phase 2 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04331119 | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas | terminated | Phase 2 | 17 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05896163 | A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.(MAPtivate-6) | terminated | Phase 1 / Phase 2 | 40 | PfizerINDUSTRY | 4 | May 6, 2026 | clinicaltrials |
| NCT03506373 | Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia | terminated | Phase 2 | 21 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05268003 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03622775 | Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant | terminated | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05090566 | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | terminated | Phase 2 | 46 | PfizerINDUSTRY | 2 | Apr 24, 2026 | clinicaltrials |
| NCT05498220 | Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 5 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03856216 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06088654 | Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 23 | Innate PharmaINDUSTRY | 3 | Apr 14, 2026 | clinicaltrials |
| NCT02681302 | Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence(CPIT001) | terminated | Phase 1 / Phase 2 | 46 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03983668 | CMP-001 for Relapsed and Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 14 | Umar FarooqOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT01453088 | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older | terminated | Phase 2 | 63 | Hackensack Meridian HealthOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT03590574 | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma | terminated | Phase 1 / Phase 2 | 20 | Autolus LimitedINDUSTRY | 2 | Mar 16, 2026 | clinicaltrials |
| NCT04676360 | Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma | terminated | Phase 2 | 10 | Jacob Soumerai, MDOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | terminated | Phase 1 / Phase 2 | 42 | GenmabINDUSTRY | 2 | Mar 4, 2026 | clinicaltrials |
| NCT03514017 | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | terminated | Phase 2 | 5 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05714345 | Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy(EXPAND) | terminated | Phase 2 | 2 | Allogene TherapeuticsINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT03919175 | Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma | terminated | Phase 2 | 18 | Massachusetts General HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03953326 | HeartPhone Cancer Survivors Trial 2019 | terminated | Phase 1 / Phase 2 | 2 | Penn State UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04205838 | Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | terminated | Phase 2 | 23 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04268277 | Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY | terminated | Phase 2 | 22 | University of UlmOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03990961 | Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) | terminated | Phase 2 | 5 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04817761 | SPARK-ALL: Calaspargase Pegol in Adults With ALL | terminated | Phase 2 / Phase 3 | 42 | Institut de Recherches Internationales ServierOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03913559 | Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | terminated | Phase 2 | 5 | St. Jude Children's Research HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 15 hours agoSource updated Sep 29, 2026source: clinicaltrials